With a 6-4 vote, the group of independent advisers to the agency narrowly concluded that results from another clinical trial are needed to assess whether the therapy, called AMX0035, can help patients.
Posted inBusiness
New ALS Treatment, AMX0035, Lacks Evidence of Benefit, FDA Panel Finds
